why choose us

First received: January 23, 2023

Clinical Trial: Expanded Access Program for Epcoritamab

Study Type: Expanded Access


Brief Summary: The purpose of this program is to provide investigational epcoritamab, an antibody also known as GEN3013 (DuoBody-CD3xCD20), in an expanded access setting for eligible patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) who have a high unmet medical need with no other treatment options. It is a requirement that patients do not qualify for an ongoing epcoritamab clinical program or are unable to participate due to logistical reasons.Access to investigational epcoritamab can be requested by…

Read more